Reata Pharmaceuticals, Inc. (RETA) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Plano, TX, United States. El CEO actual es J. Warren Huff.
RETA tiene fecha de IPO 2016-05-26, 321 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $6.57B.
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for serious and life-threatening diseases. The company's lead programs include bardoxolone methyl in Phase 3 trials for chronic kidney disease associated with Alport syndrome and pulmonary arterial hypertension, omaveloxolone in Phase 2 development for Friedreich's ataxia, and multiple Phase 2 programs targeting various forms of chronic kidney disease. Reata also has investigational compounds RTA 901 for neurological diseases and RTA 1701 for autoimmune, inflammatory, and fibrotic conditions, along with commercial access to bardoxolone for autosomal dominant polycystic kidney disease. The company has established strategic partnerships with Kyowa Kirin for bardoxolone development across Asia-Pacific markets and with AbbVie for next-generation Nrf2 activators in non-renal indications. Based in Plano, Texas, Reata was incorporated in 2002 and focuses on addressing unmet medical needs through targeted therapeutic innovation.
